GLP-1 Drugs and Spine Surgery Outcomes

A 2026 systematic review found that outcomes associated with GLP-1 receptor agonist exposure around elective spine surgery varied by procedure. Lumbar fusion studies were mostly favorable or neutral, while cervical findings were mixed and some specific fusion cohorts reported worse outcomes.^[1] This does not establish that the drugs improve or harm surgical recovery. The review was a qualitative synthesis of 23 studies, dominated by retrospective cohorts and propensity-matched database analyses rather than randomized trials.^[2]

The evidence concerns a drug class that includes semaglutide and the dual GIP and GLP-1 agonist tirzepatide. Exposure definitions, patient characteristics, operations and follow-up windows differed across the included reports. Those differences are central to reading the result.

What the systematic review examined

Ferraz and colleagues included comparative clinical studies of adults undergoing spine surgery who had documented preoperative or perioperative GLP-1 receptor agonist exposure. Eligible outcomes covered fusion, perioperative medical complications, surgical-site infection, readmission, length of stay, healthcare use or costs, and musculoskeletal outcomes. The authors reported following PRISMA 2020 principles and defined eligibility with a PICOS framework.^[2]

This was not a meta-analysis with one pooled effect estimate. The authors synthesized the studies by operation and outcome because the underlying evidence differed substantially. The review abstract does not report a combined participant count, a pooled risk ratio or a formal certainty grade. Its headline result is therefore a map of where associations looked favorable, neutral or adverse, not a class-wide treatment effect.^[2]

Lumbar fusion findings did not point one way

Across lumbar fusion studies, GLP-1 exposure was generally associated with neutral or favorable results for pseudarthrosis, infection, readmission and healthcare use. One retrospective TriNetX analysis illustrates the favorable side. It matched GLP-1 users with non-users among 5,722 elective lumbar surgery patients and reported lower pseudarthrosis at one year, 6.54% versus 8.53%, and at three years, 8.88% versus 10.77%.^[3] Reoperation and the other measured mechanical complications did not differ significantly.

A different database study in adults with type 2 diabetes undergoing transforaminal lumbar interbody fusion reported a sharply adverse association. After matching, 447 semaglutide-exposed patients were compared with 1,334 non-exposed patients. Additional lumbar fusion within one year was more likely in the exposed group, with a reported odds ratio of 11.79.^[4] The systematic review treated this as part of a procedure-specific conflict, not proof that semaglutide caused repeat surgery.^[1]

These analyses used different databases, exposure definitions and surgical populations. Propensity matching can balance recorded characteristics, but it cannot randomize treatment or remove unmeasured differences in diabetes severity, prescribing, nutrition, weight change or surgical care. A large odds ratio does not fix that design limit.

Cervical results depended on approach and follow-up

The review described anterior cervical fusion studies as generally neutral or favorable. That pattern did not extend cleanly to every cervical approach, and the available reports measured different combinations of fusion, short-term complications and readmission.^[2]

Posterior cervical evidence was less reassuring. A retrospective study matched 340 semaglutide users with 1,540 controls and reported higher odds of pseudarthrosis at two years and dysphagia. It also reported lower same-day and 90-day costs, while emergency visits and readmissions did not differ under its corrected significance threshold.^[5] Mixing these outcomes into one verdict would hide the disagreement between procedure, endpoint and follow-up.

Perioperative safety evidence remains incomplete

The review found sparse gastrointestinal safety data. None of the included studies reported postoperative pancreatitis, but absence of a reported event in this evidence set does not show that risk is zero. Preoperative treatment duration and longitudinal changes in body weight or BMI were also incompletely characterized.^[2]

Those gaps matter because the observational datasets cannot cleanly separate the medicine from the condition being treated or from changes before surgery. The authors also raised renal and hydration risk, gastrointestinal symptoms, metabolic status, and vulnerability related to nutrition or sarcopenia as factors for individualized perioperative assessment.^[2] This is clinical context, not a dosing or stop-start protocol.

What the evidence can support

The review supports a narrow conclusion: GLP-1 receptor agonist exposure has been associated with different outcomes in different spine-surgery settings. It does not support a single class-wide claim of better fusion, fewer complications or greater risk. It also cannot show that switching between semaglutide and tirzepatide would change an individual's surgical result.

For readers facing surgery, the practical question belongs with the surgical, anesthesia and prescribing teams because procedure, diabetes control, symptoms and other risks differ. Medication decisions should not be inferred from a retrospective association or changed from this review alone.

What we do not know yet

Prospective studies need clearer exposure timing, measured weight and nutritional change, consistent definitions of fusion and complications, and procedure-specific follow-up. Randomized evidence would reduce treatment-selection bias, although trials designed around perioperative medication management would still need adequate size and long-term assessment of mechanical outcomes.

Until then, the strongest reading is conditional. Neutral findings after one operation do not erase adverse findings after another, and favorable associations in matched databases do not demonstrate a protective drug effect. The 23-study review organizes a fast-growing evidence base, but it does not settle perioperative management.^[1]

Medical disclaimer: This article is for educational and journalistic purposes only and does not constitute medical advice. Peptides discussed may be classified as prescription medicines or research chemicals depending on your jurisdiction. Always consult a qualified healthcare professional before using any peptide product. PeptideMethods.com does not sell, distribute, or facilitate the sale of any peptide product.